NASH Non alcoholic Steatohepatitis Biomarkers
Market
NASH Non alcoholic Steatohepatitis Biomarkers
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
NASH Non alcoholic Steatohepatitis Biomarkers
Market Size and Growth
The NASH non-alcoholic steatohepatitis biomarkers market research reports highlight the growing demand for diagnostic tools in detecting liver diseases. The market size is projected to reach $1.3 billion by 2025, driven by an increasing prevalence of obesity and metabolic disorders worldwide. Key players in the industry are developing innovative biomarkers for early detection and monitoring of NASH.
Request Sample Report
Companies Covered (Covid
19 Impact
Covered)
◍ GENFIT SA
◍ Gilead Sciences, Inc. (GILD)
◍ AstraZeneca
◍ Novartis AG
◍ Bristol-Myers Squibb Company
◍ Allergan Plc
◍ Novo Nordisk A/S
◍ Boehringer Ingelheim
◍ Pfizer Inc
Competitive Landscape: GENFIT SA, Gilead Sciences, AstraZeneca, Novartis AG, Bristol-Myers Squibb, Allergan, Novo Nordisk, Boehringer Ingelheim, Pfizer. These companies utilize NASH biomarkers for diagnostic and therapeutic purposes, driving market growth. Sales Revenue: Gilead Sciences ($22.1 billion), AstraZeneca ($24.4 billion), Novartis AG ($51.9 billion).
Sample Report
Request
Market Segmentation
By Application
◍ Pharma & CRO Industry
◍ Hospitals
◍ Diagnostic Labs
◍ Academic Research Institutes
By Product
◍ Serum Biomarkers
◍ Hepatic Fibrosis Biomarkers
◍ Apoptosis Biomarkers
◍ Oxidative Stress Biomarkers
◍ Others
Request Sample Report
$ X Billion USD
Market Growth
Request Sample Report
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients